Copyright ©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Dec 15, 2018; 9(12): 230-238
Published online Dec 15, 2018. doi: 10.4239/wjd.v9.i12.230
Effects of glucose-lowering agents on cardiorespiratory fitness
Hidetaka Hamasaki
Hidetaka Hamasaki, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, Kagoshima 890-0046, Japan
Author contributions: Hamasaki H wrote the review.
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author to: Hidetaka Hamasaki, MD, PhD, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 890-0046, Japan.
Telephone: +81-99-2503535 Fax: +81-99-2501470
Received: August 27, 2018
Peer-review started: August 27, 2018
First decision: October 5, 2018
Revised: October 15, 2018
Accepted: November 26, 2018
Article in press: November 27, 2018
Published online: December 15, 2018
Core Tip

Core tip: What is the most effective combination of drugs and exercise for the treatment of type 2 diabetes? It has become increasingly important for clinicians to prescribe drugs that reduce cardiovascular disease and mortality in addition to their glucose-lowering effects. This review summarized the current literature investigating the effect of glucose-lowering agents on cardiorespiratory fitness. Thiazolidinediones, sodium–glucose cotransporter 2 inhibitors, and glucagon-like peptide-l receptor agonists have the potential to improve cardiorespiratory fitness; however, further research will be needed to confirm.